Tumour-targeted chemotherapy with immunoconjugates of calicheamicin

Bibliography

• TRAIL P, BIANCHI A: Monoclonalantibody drug conjugates in the treatment of cancer. Carr: Opin. Immunol.! (1999) 11:584–588.
   Google Scholar
• DUBOWCHIK G, WALKER M: Receptor-mediated and enzyme-dependent targeting of cytotoxic anti-cancer drugs. Phannacol flier. (1999) 83:67–123.
   Google Scholar
• KREITMAN RJ: Immunotoxins in cancer therapy. Carr: Opin. Immunol. (1999) 11(5):577–578.
   Web of Science ®Google Scholar
• GOLDENBERG DM: Advancing role of radiolabeled antibodies in the therapy of cancer. Cancer Innnunol. Immunother. (2003) 52(5):281–296.
   PubMed Web of Science ®Google Scholar
• MAIESE WM, LECHEVALIER MP, LECHEVALIER HA et al.: Calicheamicins, a novel family of antitumor antibiotics: taxonomy, fermentation and biological properties. J. Antibiotics (1989) 42(4):558–563.
   PubMed Web of Science ®Google Scholar
• THORSON J, SIEVERS E, AHLERT J et al.: Understanding and exploiting nature's chemical arsenal: the past, present and future of calicheamicin research. Curl: Phannaceut. Des. (2000) 6:1841–1879.
   PubMed Web of Science ®Google Scholar
• LEE M, DUNNE T, CHANG C et al.: Calicheamicins, a novel family of antibiotics. Structural elucidations of calicheamicins. J. Ana. Chen]. Soc. (1992) 114:985–987.
   Web of Science ®Google Scholar
• ZEIN N, SINHA A, MCGAHREN W, ELLESTAD G: Calicheamicin an antitumor antibiotic that cleaves double-stranded DNA site specifically. Science (1988) 240:1198–1201.
   PubMed Web of Science ®Google Scholar
• HINMAN LM, HAMANN PR, WALLACE R et al.: Preparation and characterization of monoclonal antibody conjugates of the calicheamicins: a novel and potent family of antitumor antibiotics. Cancer Res. (1993) 53:3336–3342.
   PubMed Web of Science ®Google Scholar
• HINMAN L, HAMANN P, UPESLACIS J: Preparation of conjugates to monoclonal antibodies. In: Endiyne Antibiotics as Antitumor Agents. Borders D, Doyle T (Eds), Marcel Decker, New York, USA (1995):87–106.
   Google Scholar
• HAMANN P, HINMAN L, BEYER C et al.: An anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Choice of linker. Bioconjug. Chem. (2002) 13:40–46.
   PubMed Web of Science ®Google Scholar
• HAMANN P, HINMAN L, HOLLANDER I et al.: Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Bioconjug. Chem. (2002) 13:47–58.
   PubMed Web of Science ®Google Scholar
• DIJOSEPH J, ARMELLINO D, BOGHAERT E et al.: Antibody-targeted chemotherapy with CMC-544, a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies. Blood (2004) 103: 1807-1814.
   Google Scholar
• DIJOSEPH JF, POPPLE WELL A, TICKLE S et al.: Antibody-targeted chemotherapy of B-cell lymphoma using calicheamicin conjugated to murine or humanized antibody against CD22. Cancer Immunol Immunother. (2004) (In Press).
   Google Scholar
• BOGHAERT E, SRIDHARAN L, ARMELLINO D et al.: A calicheamicin conjugate that targets Lewis Y selectively destroys Lewis Y-positive human carcinoma cells and xenografts. Gin. Cancer Res. (2004) 10(13):4538–4549.
   Web of Science ®Google Scholar
• ADAMS GP, SCHIER R, MCCALL AM et al.: High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules. Cancer Res. (2001) 61(12):4750–4755.
   PubMed Web of Science ®Google Scholar
• TENCER J, FRICK I-M, ()QUIST BW, ALM P, RIPPE B: Size selectivity of the glomerular barrier to high molecular weight proteins: upper size limitations of the shunt pathways. Kidney Int. (1998) 53:709–715.
   PubMed Web of Science ®Google Scholar
• BROSS P, BEITZ J, CHEN G et al.: Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin. Cancer Res. (2001) 7:1490–1496.
   PubMed Web of Science ®Google Scholar
• BERGER M, LEOPOLD L, DOWELL J, KORTH-BRADLEY J, SHERMAN M: Licensure of gemtuzumab ozogamicin for the treatment of selected patients 60 years of age or older with acute myeloid leukemia in first relapse. Invest. New Drugs (2002) 20:395–406.
   PubMed Web of Science ®Google Scholar
• ANDREWS R, SINGER J, BERNSTEIN I: Precursors of colony-forming cells in humans can be distinguished from colony-forming cells by expression of the CD33 and CD34 antigens and light scatter properties. Exp. Med. (1989) 169:1721–1731.
   PubMed Web of Science ®Google Scholar
• SIEVERS E, APPLEBAUM F, SPIELBERGER R et al.: Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: A Phase I study of an anti-CD33 calicheamicin immunoconjugate. Blood (1999) 93:3678–3684.
   PubMed Web of Science ®Google Scholar
• SIEVERS E, LARSON R, STADMAUER E et al.: Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. Clin. Oncol (2001) 19:3244–3254.
   Web of Science ®Google Scholar
• LARSON R, BOOGAERTS M, ESTEY E et al.: Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin). Leukemia (2002) 16:1627–1636.
   PubMed Web of Science ®Google Scholar
• SIEVERS E, LARSON R, ESTEY E et al.:Final report of prolonged disease-free survival in patients with acute myeloid leukemia in first relapse treated with gemtuzumab ozogamicin followed by hematopoietic stem cell transplantation. Blood (2002) 100:89a.
   PubMed Web of Science ®Google Scholar
• LINENBERGER M, HONG T, FLOWERS D et al: Multidrug-resistance phenotype and clinical responses to gemtuzumab ozogamicin. Blood (2001) 98:988–994.
   PubMed Web of Science ®Google Scholar
• NAITO K, TAKESHITA A, SHIGENO K et al.: Calicheamicin-conjugated humanized anti-CD33 monoclonal antibody (gemtuzumab zogamicin, CMA-676) shows cytocidal effect on CD33-positive leukemic cell lines but is inactive on P-glycoprotein-expressing sublines. Leukemia (2000) 14:1436–1443.
   PubMed Web of Science ®Google Scholar
• MATSUI H, TAKESHITA A, NAITO K et al.: Reduced effect of gemtuzumab ozogamicin (CMA-676) on P-glycoprotein and/or CD34-positive leukemia cells and its restoration by multidrug resistance modifiers. Leukemia (2002) 16:813–819.
   PubMed Web of Science ®Google Scholar
• WALTER R, LINENBERGER M, HONG T, RADEN W, BERNSTEIN I: Multidrug resistance protein (MRP) attenuates gemtuzumab ozogamicin (GO)-induced cytotoxicity in acute myeloid leukemia (AML). Blood (2003) 100(11):2246–225b.
   Google Scholar
• GILES F, KANTARJIAN H, KORNBLAU S et al.: Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation. Cancer (2001) 92:406–413.
   PubMed Web of Science ®Google Scholar
• NEUMEISTER P, EIBL M, ZINKE-CERWENKA W, SCARPATETTI M, SILL H, LINKESCH W: Hepatic veno-occlusive disease in two patients with relapsed acute myeloid leukemia treated with anti-CD33 calicheamicin (CMA-676) immunoconjugate. Ann. Hematol (2001) 80:119–120.
   PubMed Web of Science ®Google Scholar
• RAJVANSHI P, SHULMAN H, SIEVERS E, MCDONALD G: Hepatic sinusoidal onstruction after gemtuzumab ozogamicin (Mylotarg) therapy. Blood (2002) 99:2310–2314.
   PubMed Web of Science ®Google Scholar
• CHEN A, LUGER S, SICKLES C et al.:Gemtuzumab ozogamicin (IVIylotargTm) therapy for relapsed AML after hematopoetic stem cell transplant: efficacy and incidence of hepatic veno-occlusive disease. Bone Marrow Transplant. (2002) 9:23–28.
   Web of Science ®Google Scholar
• DOLL C, YARBRO J: Vascular toxicity associated with antineoplastic agents. Semin. Oncol (1992) 19:580–596.
   PubMed Web of Science ®Google Scholar
• RICHARDSON P, GUINAN E: Hepatic veno-occlusive disease following hematopoietic stem cell transplantation. Acta Haematol (2001) 106:57–68.
   PubMed Web of Science ®Google Scholar
• ERBA H, STADTMAUER E, LARSON R et al.: Results of a multivariate analysis to determine factors contributing to the risk of developing hepatic veno-occlusive disease (VOD) following treatment with gemtuzumab ozogamicin. Blood (2002) 100:339a.
   Web of Science ®Google Scholar
• WADLEIGH M, RICHARDSON PG, ZAHRIEH D et al.: Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation. Blood (2003) 102(5):1578–1582.
   PubMed Web of Science ®Google Scholar
• ALVARADO Y, TSIMBERIDOU A, KANTARJIAN H et al.: Pilot study of Mylotarg, idarubicin and cytarabine combination regimen in patients with primary resistant or relapsed acute myeloid 1451 leukemia. Cancer Chemother. Pharmacol (2003) 51:87–90.
   PubMed Web of Science ®Google Scholar
• TSIMERIDOU A, ESTEY E, CORTES J et al: Gemtuzumab, fludarabine, cytarabine, and cyclosporine in patients with newly diagnosed acute myelogenous leukemia or high-risk myelodysplastic syndromes. Cancer (2003) 97(6):1481–1487.
   PubMed Web of Science ®Google Scholar
• BACCARANI M, DURRANT S, LINKESCH W et al.: Preliminary report of a Phase II study of the safety and efficacy of gemtuzumab ozogamicin (Mylotarg) given in combination with cytarabine in patients with acute myeloid leukemia. Blood (2002) 100(11):341a.
   PubMed Web of Science ®Google Scholar
• DE ANGELO D, SCHIFFER C, AMREIN P et al.: Interim analysis of a Phase II study of the safety and efficacy of gemtuzumab ozogamicin (Mylotarg) given in combination with cytarabine and daunorubicin in patients 60 years old with untreated acute myeloid leukemia. Blood (2002) 100(11):198a-199a.
   Google Scholar
• ESTEY E, GILES F, BERAN M et al: Experience with gemtuzumab ozogamycin ('mylotarg') and all-trans retinoic acid in untreated acute promyelocytic leukemia. Blood (2002) 99:4222–4224.
   PubMed Web of Science ®Google Scholar
• PETTI M, PINAZZI MB, DIVERIO D et al.: Prolonged molecular remission in advanced acute promyelocytic leukaemia after treatment with gemtuzumab ozogamicin (Mylotarg CMA-676). Br. J. Haematol (2001) 115:63–65.
   PubMed Web of Science ®Google Scholar
• VON MENSDORFF-POUILLY S, SNIJDEWINT FG, VERSTRAETEN AA, VERHEIJEN RH, KENEMANS P: Human MUC1 mucin: a multifaceted glycoprotein. hat. J. Biol. Markers (2000) 15(4):343–356.
   PubMed Web of Science ®Google Scholar
• DAVIES Q, PERKINS AC, FRIER M, WATSON S, LALANI E, SYMONDS EM: The effect of circulating antigen on the biodistribution of the engineered human antibody hCTM01 in a nude mice model. Eur. J. Nucl. Med. (1997) 24(2):206–209.
   PubMedGoogle Scholar
• DAVIES Q, PERKINS AC, ROOS JC et al.: An immunoscintigraphic evaluation of the engineered human monoclonal antibody (hCTM01) for use in the treatment of ovarian carcinoma. Br. Obstet. Cynaecol (1999) 106(1):31–37.
   PubMedGoogle Scholar
• VAN HOF AC, MOLTHOFF CE DAVIES Q: Biodistribution of (111)indium-labeled engineered human antibody CTMO1 in ovarian cancer patients: influence of protein dose. Cancer Res. (1996) 56(22):5179–5185.
   PubMed Web of Science ®Google Scholar
• GILLESPIE AM, BROADHEAD TJ, CHAN SY et al.: Phase I open study of the effects of ascending doses of the cytotoxic immunoconjugate CMB-401 (hCTM01-calicheamicin) in patients with epithelial ovarian cancer. Ann. Oncol (2000) 11(6):735–741.
   PubMed Web of Science ®Google Scholar
• CHAN SY, GORDON AN, COLEMAN RE et al.: A Phase II study of the cytotoxic immunoconjugate CMB-401 (hCTM01-calicheamicin) in patients with platinum-sensitive recurrent epithelial ovarian carcinoma. Cancer Immunol Immunother. (2003) 52(4):243–248.
   PubMed Web of Science ®Google Scholar
• CROCKER PR, VARKI A: Siglecs, sialic acis, and innate immunity. Trends Immunol (2001) 22:337–342.
   PubMed Web of Science ®Google Scholar
• LI JL, SHEN GL, GHETIE MA et al.: The epitope specificity and tissue reactivity of four murine monoclonal anti-CD22 antibodies. Cell. Immunol (1989) 118:85–99.
   PubMed Web of Science ®Google Scholar
• HANNA R, ONG G, MATTES M: Processing of antibodies bound to B-cell lymphomas and other hematological malignancies. Cancer Res. (1996) 56:3062–3068.
   PubMed Web of Science ®Google Scholar
• DIJOSEPH JF, GOAD ME, DOUGHER MM et al: Potent and specific antitumour efficacy of CMC-544, a CD22-targeted immunoconjugate of calicheamicin, against systemically disseminated B-cell lymphoma. Clin. Cancer Res. (2004) (In Press). Websites
   Google Scholar
• http://www.bexxar.com Information on Bexxar.
   Google Scholar
• http://www.zevalin.com Information on Zevalin.
   Google Scholar
• http://www.ligand.com/pdf/ONTAKPI.pdf Information on ONTAK.
   Google Scholar